8h30 – 8h35 : Introduction
Dr Eric Baudin -Villejuif
Chair : Pr Désirée Déandreis and Dr Julien Hadoux

8h35 – 9h30 : Undestanding our targets in ET and NET Genetic and epigenetic of refractory thyroid cancer
Dr Inigo Landa - Boston
Genetic and epigenetics of malignant Pheochromocytomas and paragangliomas: which lessons for NET?
Dr Judith Favier - Paris

9h30 – 9h50 : BRAF, RET, Fusions, TMB, MSI : quelle meilleure méthode pour ne rien rater ?
Dr Ludovic Lacroix - Villejuif

9h50 – 10h15 : Vaccins en oncologie des tumeurs endocrines: quels résultats? Vaccine in endocrine oncology, which results?
Pr Alfredo Berruti - Brescia

10h15 – 10h45 : Pause

Chair : Pr Désirée Déandreis and Dr Julien Hadoux

10h45 – 11h45 : Radioloigand therapy from one model to the other: which lessons as compared to radioiodine in DTC?
- Advdanced MTC: not targetable still?
Dr Emmanuel Christ - Bale
- What do we learn from radioligand therapy in prostate cancer?
Pr Désirée Déandréis - Villejuif
- What do we learn from Radioligand therapy in NET?
Dr Eric Baudin - Villejuif
Discussion

11h45 - 13h00 : Intégrer les mécanismes de résistance en oncologie endocrinienne dans la séquence thérapeutique / Think in terms of mechanism of resistance in the sequencing of therapeutic lines:
- Should we trigger high TMB?
Dr Julien Hadoux – Villejuif
- Mechanisms of Resistance to BRAF inhibition?
Mme Corinne Dupuy – Villejuif
- RET specific-inhibitoirs or MKI, as first line, in advanced MTC?
Dr Mattias Kroiss – Munich
- Is there a best MKI sequencing strategy in endocrine and urological tumors ?: a cross- analysis of two specialized oncologists
Dr Sophie Moog ( endocrinology)– Villejuif
Dr Ronan Flippot (urology) - Villejuif

13h00 - 14h00 : Cocktail déjeunatoire et visite des stands